Gilead Sciences, Inc. vs Rigetti Computing Inc — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while Rigetti Computing Inc trades at $14.02 (market cap $4.72B). The key difference: Gilead Sciences, Inc. is far larger — about 38.6× Rigetti Computing Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Rigetti Computing Inc for 35 Days on average.
| GILD | RGTI | |
|---|---|---|
Market Cap | $182.40B | $4.72B |
Volume | 4,469,821 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $155.80 | $56.34 |
52-Week Low | $116.74 | $12.90 |
Typical Hold Time | 111 Days | 35 Days |
Enterprise Value | $205.46B | $4.33B |
Dividend Yield | 2.23% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
RGTI trades at $14.04, down 3.77% today, with a bearish technical signal despite bullish oscillators. The company shows minimal revenue of $7.09M in 2025 with a massive net loss of -$216.21M, resulting in negative profit margins. Analyst consensus is strongly bullish with 6 buy ratings and a $21.67 price target, representing 54% upside. Recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC strategy with partners like HPE.
While analyst optimism and quantum computing potential offer significant upside, RGTI faces substantial execution risks with negative cash flow, high valuation multiples, and intense competition. The stock presents high-risk/high-reward potential for investors willing to tolerate volatility in exchange for quantum computing exposure, but requires careful monitoring of commercialization progress and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →